secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-103118
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences reports FY2025 net loss of $87M; Phase 3 canvuparatide on track for Q3 2026
--------------------------------------------------------------------------------

- Net loss FY2025 $87.0M vs $61.9M in 2024; R&D expenses $79.2M, up from $57.4M.
- Pro forma cash & investments $459.1M including $85.4M ATM net proceeds; runway into 2029.
- Phase 3 trial of once-weekly canvuparatide for hypoparathyroidism to initiate Q3 2026 after successful End-of-Phase 2 FDA meeting.
- MBX 4291 (obesity) 12-week MAD data expected Q4 2026; two additional obesity candidates to be nominated in Q2 and Q3 2026.
- Appointed Laurie Stelzer to Board and Karen Basbaum as CBO in early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526103118/0001193125-26-103118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526103118/mbx-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-103118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer